scholarly journals Should We Establish Standards of Care for Management of Elderly Patients with Inflammatory Bowel Disease?

2015 ◽  
Vol 29 (5) ◽  
pp. 236-236 ◽  
Author(s):  
Subrata Ghosh ◽  
Marietta Iacucci
Keyword(s):  
Inflammatory Bowel Disease ◽  
Elderly Patients ◽  
Bowel Disease ◽  
Standards Of Care ◽  
Inflammatory Bowel

scholarly journals Impact of immunosuppressants on SARS-CoV-2 infection in elderly patients with inflammatory bowel disease

2021 ◽  
Author(s):  
Margalida Calafat ◽  
Carlos González-Muñoza ◽  
Marta Fortuny ◽  
Cristina Roig ◽  
Anna Calm ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Elderly Patients ◽  
Bowel Disease ◽  
Inflammatory Bowel

scholarly journals Vedolizumab Is Safe and Effective in Elderly Patients with Inflammatory Bowel Disease

2017 ◽  
Vol 23 (4) ◽  
pp. E17 ◽  
Author(s):  
Udayakumar Navaneethan ◽  
Timothy Edminister ◽  
Xiang Zhu ◽  
Kiran Kommaraju ◽  
Sarah Glover
Keyword(s):  
Inflammatory Bowel Disease ◽  
Elderly Patients ◽  
Bowel Disease ◽  
Inflammatory Bowel

scholarly journals DOP49 Effectiveness and safety of vedolizumab in a matched cohort of elderly and young Inflammatory Bowel Disease patients - LIVE Study-Group

2021 ◽  
Vol 15 (Supplement_1) ◽  
pp. S085-S085
Author(s):  
D Pugliese ◽  
G Privitera ◽  
A Armuzzi
Keyword(s):  
Inflammatory Bowel Disease ◽  
Elderly Patients ◽  
Bowel Disease ◽  
Real Life ◽  
The Elderly ◽  
Primary Endpoints ◽  
Real Life Data ◽  
Endoscopic Remission ◽  
Inflammatory Bowel ◽  
Biochemical Remission

Abstract Background Vedolizumab is the first biologic tested for the treatment of elderly patients with moderate-to-severely active ulcerative colitis (UC) and Crohn’s disease (CD) in the GEMINI program. However, little real-life data have been reported on its use in the elderly population. In this work, we present data on vedolizumab effectiveness and safety in a large cohort of elderly UC and CD patients matched to younger patients. Methods The Long-term Italian Vedolizumab Effectiveness (LIVE) study included CD and UC patients started on vedolizumab from April 2016 to June 2017 at 47 centers of the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD). Elderly (E-) patients (≥ 65-year-old) were included for this analysis and matched 1:2 to younger (Y-) patients; patients were then prospectively followed-up until June 2019. Primary endpoints were vedolizumab persistence and safety. Results Of 1111 patients, 198 E-patients (mean age 71 ± 5 years; 108 UC,90 CD) were included in the analysis and matched with 396 Y-patients (45 ±12 years; 205 UC,191 CD). After matching, the 2 cohorts were overall comparable, but patients in the Y-group were significantly more likely to have perianal disease, previous exposure to immunosuppressants, and to anti-TNF-α and less likely to be on concomitant steroids at baseline. For UC, persistence in the E- and Y-groups were 69.9% vs and 81.4% at 12 months, and 51.4% vs 67.6% at 24 months (p<0.05 for both). Significant differences were also observed in terms of steroid-free clinical remission (SFCR) (31.5% vs 42.9%,32.4% vs 42.9% at 12 and 24 months, p<0.05 for both) and biochemical remission (22.2% vs 38%,25.9% vs 40.5% at 12 and 24 months, p<0.05 for both). Endoscopic remission was observed in 17/75 (22.7%) E-patients and 50/141 (35.5%) Y-patients (p=0.05). For CD, persistence was 75.6% vs 75.1% at 12 months, 52.4% vs 59.4% at 24 months, for the E- and Y- group respectively (p=ns for both). Similarly, rates of SFCR were comparable between the 2 cohorts. Notably, a significantly higher rate of biochemical remission was observed in the Y-group at 24 months (21.1% vs 30.9%, p<0.05). Endoscopic remission was observed in 13/48 (27.1%) E-patients and 25/98 (28.1%) Y-patients (p=ns). A total of 51 and 94 adverse events (AEs) were observed in the E-group and Y-group, respectively: the rate of AEs was comparable between the 2 groups (p=ns). Of note, E-patients had a higher likelihood of suspending vedolizumab due to AEs (p<0.05). Conclusion The data show that vedolizumab can be considered a safe option in elderly patients; however, its efficacy in elderly UC patients (in terms of persistence, SFCR and biochemical remission) seems to be reduced compared to younger UC patients, while no difference was observed in CD.

scholarly journals New Zealand National Audit of Outpatient Inflammatory Bowel Disease Standards of Care

2020 ◽  
Vol Volume 13 ◽  
pp. 285-292
Author(s):  
Robert Hackett ◽  
Richard Gearry ◽  
Christine Ho ◽  
Andrew McCombie ◽  
Megan Mackay ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
New Zealand ◽  
Bowel Disease ◽  
Standards Of Care ◽  
National Audit ◽  
Inflammatory Bowel

scholarly journals Maintaining the Quality Standards of Care for Inflammatory Bowel Disease Patients During the COVID-19 Pandemic

2020 ◽  
Vol 18 (8) ◽  
pp. 1882-1883 ◽  
Author(s):  
Mariangela Allocca ◽  
Gionata Fiorino ◽  
Federica Furfaro ◽  
Daniela Gilardi ◽  
Simona Radice ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Quality Standards ◽  
Standards Of Care ◽  
Inflammatory Bowel
Sign in / Sign up

Export Citation Format

Share Document